Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.

Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia.

To determine whether the use of idarubicin+cytarabine (IA) is more effective than the use of daunorubicin+cytarabine (DA) as induction chemotherapy for patients with newly diagnosed acute myeloid leukaemia.A computer-based search was performed. Randomised trials comparing IA with DA as induction the...

Full description

Bibliographic Details
Main Authors:	Jing Wang, Yong-Gong Yang, Min Zhou, Jing-Yan Xu, Qi-Guo Zhang, Rong-Fu Zhou, Bing Chen, Jian Ouyang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3622517?pdf=render

Similar Items

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
by: Gabriela Rodríguez-Macías, et al.
Published: (2023-06-01)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
by: Emmanuel Gyan, et al.
Published: (2022-06-01)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
by: Dennis, M, et al.
Published: (2013)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
by: Qingguo Liu, et al.
Published: (2020-07-01)

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia
by: Kenneth F. Bradstock, et al.
Published: (2016-12-01)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
by: Xiaohui Suo, et al.
Published: (2023-05-01)

Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.
by: Felix Jost, et al.
Published: (2019-01-01)

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial
by: Jun Li, et al.
Published: (2022-12-01)

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia
by: Wheatley, D, et al.
Published: (1998)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01)

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
by: Prashanth Ashok Kumar MBBS, et al.
Published: (2022-11-01)

Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
by: K. Brandt, et al.
Published: (2010-10-01)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
by: Anthony P. Schwarer, et al.
Published: (2018-12-01)

P543: TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST-LINE CYTARABINE-BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT-AML TRIAL
by: M. Jädersten, et al.
Published: (2022-06-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin
by: Erin A. Dean, et al.
Published: (2022-08-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Cytarabine-Induced Encephalitis
by: Christine Lenfant, et al.
Published: (2021-09-01)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
by: Mayer LD, et al.
Published: (2019-05-01)

Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
by: Jun-Feng Zhu, et al.
Published: (2022-10-01)

Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
by: Sarah M Leonard, et al.
Published: (2014-01-01)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
by: Marie C. Fortin, et al.
Published: (2023-11-01)

Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
by: Chengzhi Xie, et al.
Published: (2013-01-01)

Effect of Chemotherapy Cytarabine and Acute Myeloid Leukemia on the Development of Spermatogenesis at the Adult Age of Immature Treated Mice
by: Bara’ah Khaleel, et al.
Published: (2022-04-01)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
by: Rebecca Anderson, et al.
Published: (2022-03-01)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
by: Huali Sun MD, et al.
Published: (2023-10-01)

Treatment of acute erythroleukaemia with high‐dose cytarabine in a cat with feline leukaemia virus infection
by: Da Sol Park, et al.
Published: (2022-01-01)

Low-Dose Cytarabine versus Best Supportive Care for Patients with Acute Myeloid Leukaemia Unfit for the Standard of Care: Egyptian Centre Experience
by: Amrallah Mohammed, et al.
Published: (2021-07-01)

High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.
by: Wei Li, et al.
Published: (2014-01-01)

High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
by: Qiang Gong, et al.
Published: (2015-01-01)

The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
by: Xiaohong Zheng, et al.
Published: (2020-07-01)

Results of a pharmacoeconomic analysis of the rationality of the use of acute myeloid leukemia chemotherapy regimens with the use of various doses of cytarabine
by: Panfilova Hanna, et al.
Published: (2021-01-01)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
by: Nienke Visser, et al.
Published: (2021-02-01)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
by: Nizar Serhan, et al.
Published: (2020-06-01)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
by: Amanda Lopes Maia Rodrigues, et al.
Published: (2020-07-01)

Corneal epithelial microcysts due to high dose Cytarabine administration in acute myeloid leukemia
by: Tuba Hilkay Karapınar, et al.
Published: (2012-03-01)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
by: Sook-Kyoung Heo, et al.
Published: (2020-12-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol
by: Taynah Cascaes Puty, et al.
Published: (2019-05-01)

Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
by: Young Hoon Park, et al.
Published: (2022-07-01)